

Attorney Docket No. 5390 200-US  
Dorwald et al.  
Serial No 09/548,081, Filed April 12, 2000

Attorney Docket No.: 5390.200-US

**RECEIVED  
CENTRAL FAX CENTER**

**DEC 16 2004  
PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Dorwald et al. Confirmation No.: 5691  
Application No.: 09/548,081 Group Art Unit: 1624  
Filed: April 12, 2000 Examiner: Liu, Hong  
For: Substituted Imidazoles, Their Preparation and Use

**NOTICE OF APPEAL FROM THE EXAMINER  
TO THE BOARD OF PATENT APPEALS AND INTERFERENCES**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicant hereby appeals to the Board of Patent Appeals and Interferences from the last decision mailed June 25, 2004, of the Examiner finally rejecting claims numbered 102-105.

Please charge the required fee, estimated to be \$500, and any additional fees necessary for timely filing of this paper, and credit any overpayments to Novo Nordisk, Inc., Deposit Account No. 14-1447.

A copy of this sheet is enclosed.

Respectfully submitted,



Date: December 16, 2004

Rosemarie R. Wilk-Orescan  
Registration Number 45, 220  
Novo Nordisk, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5969

**CUSTOMER NUMBER  
23650**

PATENT TRADEMARK OFFICE

Attorney Docket No. 5390.200-US  
Dorwald et al.  
Serial No. 09/548,081, Filed April 12, 2000

Attorney Docket No.: 5390.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Dorwald et al. Confirmation No.: 5691  
Application No.: 09/548,081 Group Art Unit: 1624  
Filed: April 12, 2000 Examiner: Liu, Hong  
For: Substituted Imidazoles, Their Preparation and Use

**NOTICE OF APPEAL FROM THE EXAMINER  
TO THE BOARD OF PATENT APPEALS AND INTERFERENCES**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicant hereby appeals to the Board of Patent Appeals and Interferences from the last decision mailed June 25, 2004, of the Examiner finally rejecting claims numbered 102-105.

Please charge the required fee, estimated to be \$500, and any additional fees necessary for timely filing of this paper, and credit any overpayments to Novo Nordisk, Inc., Deposit Account No. 14-1447.

A copy of this sheet is enclosed.

Respectfully submitted,



Date: December 16, 2004

Rosemarie R. Wilk-Orescan  
Registration Number 45, 220  
Novo Nordisk, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5969

**CUSTOMER NUMBER**

**23650**

PATENT TRADEMARK OFFICE